Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions

被引：46

作者：

Schweighardt, B ^{[1
]}

Ortiz, GM

Grant, RM

Wellons, M

Miralles, GD

Kostrikis, LG

Bartlett, JA

Nixon, DF

机构：

[1] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA

[2] Duke Univ, Med Ctr, Ctr AIDS Res, Durham, NC USA

[3] Trimeris Pharmaceut, Durham, NC USA

[4] Univ Athens, Sch Med, GR-11527 Athens, Greece

来源：

AIDS | 2002年 / 16卷 / 17期

关键词：

D O I：

10.1097/00002030-200211220-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the emergence of drug-resistant viral mutations in chronically HIV-infected individuals undergoing structured treatment interruptions (STI). The protease mutation M46L and the reverse transcriptase mutations K101E and K103N were detected at the end of the second or third STI. We conclude that the repeated abrupt termination and resumption of certain antiretroviral drug regimens during STI therapy may lead to the development of drug resistance in chronically HIV-infected individuals.

引用

页码：2342 / 2344

页数：3

共 50 条

[1] Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions
Martinez-Picado, J
Morales-Lopetegi, K
Wrin, T
Prado, JG
Frost, SDW
Petropoulos, CJ
Clotet, B
Ruiz, L
AIDS, 2002, 16 (06) : 895 - 899
[2] Mutation takes no vacation: Can structured treatment interruptions increase the risk of drug-resistant HIV-1?
Dorman, KS
Kaplan, AH
Lange, K
Sinsheimer, JS
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (05) : 398 - 402
[3] Detection of minor populations of drug-resistant viruses in patients undergoing structured treatment interruptions
Metzner, KJ
Bonhoeffer, S
Fischer, M
Karanicolas, R
Weber, R
Hirschel, B
Kostrikis, LG
Günthard, HF
ANTIVIRAL THERAPY, 2002, 7 : S96 - S96
[4] The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure
Stella-Ascariz, Natalia
Ramon Arribas, Jose
Paredes, Roger
Li, Jonathan Z.
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S847 - S850
[5] Infrequent transmission of HIV-1 drug-resistant variants
Yerly, S
Jost, S
Telenti, A
Flepp, M
Kaiser, L
Chave, JP
Vernazza, P
Battegay, M
Furrer, H
Chanzy, B
Burgisser, P
Rickenbach, M
Gebhardt, M
Bernard, MC
Perneger, T
Hirschel, B
Perrin, L
ANTIVIRAL THERAPY, 2004, 9 (03) : 375 - 384
[6] Primary HIV-1 Drug-Resistant Minority Variants
Chimukangara, Benjamin
Samuel, Reshmi
Naidoo, Kogieleum
de Oliveira, Tulio
AIDS REVIEWS, 2017, 19 (02) : 89 - 96
[7] Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome
Jakobsen, Martin R.
Tolstrup, Martin
Sogaard, Ole S.
Jorgensen, Louise B.
Gorry, Paul R.
Laursen, Alex
Ostergaard, Lars
CLINICAL INFECTIOUS DISEASES, 2010, 50 (04) : 566 - 573
[8] Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection
Metzner, Karin J.
Scherrer, Alexandra U.
Preiswerk, Benjamin
Joos, Beda
von Wyl, Viktor
Leemann, Christine
Rieder, Philip
Braun, Dominique
Grube, Christina
Kuster, Herbert
Boeni, Juerg
Yerly, Sabine
Klimkait, Thomas
Aubert, Vincent
Furrer, Hansjakob
Battegay, Manuel
Vernazza, Pietro L.
Cavassini, Matthias
Calmy, Alexandra
Bernasconi, Enos
Weber, Rainer
Guenthard, Huldrych F.
JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (07): : 1102 - 1112
[9] Emergence of Minor Drug-Resistant HIV-1 Variants after Triple Antiretroviral Prophylaxis for Prevention of Vertical HIV-1 Transmission
Hauser, Andrea
Sewangi, Julius
Mbezi, Paulina
Dugange, Festo
Lau, Inga
Ziske, Judith
Theuring, Stefanie
Kuecherer, Claudia
Harms, Gundel
Kunz, Andrea
PLOS ONE, 2012, 7 (02):
[10] Structured treatment interruptions to control HIV-1 and limit drug exposure
Montaner, LJ
TRENDS IN IMMUNOLOGY, 2001, 22 (02) : 92 - 96

← 1 2 3 4 5 →